Edition:
United States

Alexion Pharmaceuticals Inc (ALXN.OQ)

ALXN.OQ on NASDAQ Stock Exchange Global Select Market

127.55USD
4:00pm EDT
Change (% chg)

$-1.25 (-0.97%)
Prev Close
$128.80
Open
$128.49
Day's High
$128.85
Day's Low
$125.35
Volume
443,468
Avg. Vol
533,189
52-wk High
$141.81
52-wk Low
$92.57

About

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical development programs include Soliris (eculizumab... (more)

Overall

Beta: 1.54
Market Cap(Mil.): $28,881.75
Shares Outstanding(Mil.): 224.24
Dividend: --
Yield (%): --

Financials

  ALXN.OQ Industry Sector
P/E (TTM): 92.09 30.96 35.38
EPS (TTM): 1.40 -- --
ROI: 2.48 12.01 11.72
ROE: 3.42 13.30 16.38

Drugmakers Jazz, Alexion, Lundbeck to pay $123 million to resolve U.S. charity kickback probe

BOSTON Three drugmakers will pay $122.6 million to resolve claims they used charities that help cover Medicare patients' out-of-pocket drug costs as a way to pay kickbacks aimed at encouraging use of their medications, including some expensive ones.

Apr 04 2019

UPDATE 3-Drugmakers Jazz, Alexion, Lundbeck to pay $123 mln to resolve U.S. charity kickback probe

BOSTON, April 4 Three drugmakers will pay $122.6 million to resolve claims they used charities that help cover Medicare patients' out-of-pocket drug costs as a way to pay kickbacks aimed at encouraging use of their medications, including some expensive ones.

Apr 04 2019

Alexion reaches $13 million deal in U.S. drug charity kickback probe

Alexion Pharmaceuticals Inc, the maker of an expensive blood disorder treatment, has agreed to pay $13 million to resolve a U.S. Department of Justice probe into its financial support of charities that help Medicare patients cover out-of-pocket drug costs.

Feb 07 2019

Alexion wins early U.S. approval for rare blood disorder drug

The U.S. Food and Drug Administration approved on Friday Alexion Pharmaceuticals Inc's rare blood disorder drug Ultomiris, an early backing that also solidifies the company's dominant market position.

Dec 21 2018

UPDATE 2-Alexion wins early U.S. approval for rare blood disorder drug

Dec 21 The U.S. Food and Drug Administration approved on Friday Alexion Pharmaceuticals Inc's rare blood disorder drug Ultomiris, an early backing that also solidifies the company's dominant market position.

Dec 21 2018

U.S. FDA approves Alexion Pharma's blood disorder drug

Dec 21 The U.S. Food and Drug Administration has approved Alexion Pharmaceuticals Inc's blood disorder drug Ultomiris, the pharma regulator's website showed https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761108 on Friday.

Dec 21 2018

Earnings vs. Estimates